Norms Impact

Trump Admits on Live TV That He Told CEO to Give Him Piece of Company

Trump used the Oval Office to press a CEO for an ownership “chunk,” collapsing the boundary between public policy power and private property extraction.

Executive

Nov 6, 2025

⚖ Legal Exposure

Ethics Violation

Likely Unlawful

Potentially Criminal

Likely Criminal

Publicly asking a pharmaceutical CEO to “give” the government a “piece of the company” in the Oval Office during policy discussions creates serious corruption- and ethics-related exposure as a solicitation/pressure event. However, the article does not allege any transfer, agreement, or specific official act exchanged, leaving key elements of bribery/extortion incomplete. This is best characterized as a significant investigative red flag pending evidence of money-to-action alignment.

Sources

https://newrepublic.com/post/202843/trump-tells-ceo-give-me-piece-company-novo-nordisk

Summary

In the Oval Office, Donald Trump told Novo Nordisk CEO Maziar Mike Doustdar on live television that he had been asking for “a piece of the company” and urged him to give the United States “a nice big chunk.” That public request, made during a White House event tied to drug-pricing policy, signals a willingness to blend sovereign regulatory power with ownership demands toward a private firm. The practical consequence is a blurred line between public health negotiation and state leverage, inviting coercive governance and corrosive precedent for how companies are pressured by our government.

Reality Check

Threatening democratic stability starts when the presidency treats regulatory power as leverage to demand equity—because citizens’ rights and markets both erode when government can extract “a piece of the company” on command. On these facts alone, the conduct reads less like a prosecutable shakedown and more like an overt violation of anti–quid-pro-quo governance norms: the office is being used to float a personal-style extraction in the middle of a policy announcement. If any ownership demand were tied to official acts or conditioned regulatory benefits, that could implicate federal bribery and extortion frameworks (18 U.S.C. § 201; Hobbs Act extortion under color of official right, 18 U.S.C. § 1951), but the provided record does not establish the necessary exchange. What we can see clearly is a precedent of weaponizing the state’s negotiating posture to normalize coerced “stakes,” inviting government-by-pressure rather than law.

Legal Summary

Legal Analysis

18 U.S.C. § 201(b) — Bribery of public officials (quid pro quo)

The President publicly stated he has been “asking for” a “piece of the company” from a pharmaceutical CEO while conducting official business (press conference on drug pricing), creating an appearance of leveraging office for a thing of value.
Article context does not describe any completed transfer, specific official act offered/undertaken in exchange, or an agreement; the statement reads as pressure/solicitation but the quid-pro-quo linkage is not factually developed.

18 U.S.C. § 201(c) — Illegal gratuities (thing of value because of official acts)

The request for an ownership “chunk” made in the Oval Office in the midst of policy discussions could be construed as seeking a thing of value in connection with governmental action affecting the industry.
Key gap: no allegation of an actual payment/transfer or that any official act was taken “for or because of” the thing of value.

18 U.S.C. § 872 — Extortion by officers or employees of the United States (under color of official right)

“Give us a piece of the company like I’ve been asking for” to a regulated-industry executive during a government event can be read as using the power/prestige of office to pressure a private party for value.
Key gaps: the article does not allege a demand backed by an explicit threat, nor that anything was obtained.

5 C.F.R. Part 2635 — Standards of Ethical Conduct (misuse of position / seeking gifts)

Requesting an ownership stake from a private company in a public official setting indicates potential misuse of position and solicitation of a prohibited gift/financial interest, even if framed as for the “United States.”

Conclusion: The described conduct is an investigative red flag for misuse of office/solicitation and potential “color of right” pressure, but the article does not establish a completed transfer or a concrete exchange tying value to an official act, so it reads more as procedural/ethical exposure than fully formed prosecutable structural corruption on these facts alone.

Media

View media post

Detail

During a White House press conference in the Oval Office on Thursday focused on lowering costs for weight-loss drugs, President Donald Trump appeared alongside health officials and executives from Novo Nordisk and Eli Lilly.

When a reporter asked about Novo Nordisk’s acquisition of an obesity biotech company, Trump addressed Novo Nordisk CEO Maziar Mike Doustdar and said, “Maybe you should give us a piece of the company like I’ve been asking for, give the United States a nice big chunk of the company.” Doustdar chuckled and did not respond to the request, instead continuing to explain the acquisition.

The event also featured Trump reiterating claims about lowering drug prices and announcing that the government would launch a website to sell prescription drugs directly to the public. The context notes that the government has already taken stakes in multiple American companies, including U.S. Steel, Intel, Trilogy Metals, Lithium Americas, and MP Materials.

Trump: Iran asked me to be Supreme Leader, but I said no thanks

‘Men need to be perp-walked’ after Epstein files release, Massie tells BBC

Buried.News

Trump fires Kristi Noem as Homeland Security Secretary

The Trump gold coin is not normal : Consider This from NPR

White House Confronted Over Huge Bets Made Minutes Before Trump’s Big War Move